Search clinical trials for: inhaled budesonide and formeterol plus oral montelukast

Total 473 results

GlaxoSmithKline

Completed

A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma

Asthma

Argentina
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS) (MARS)

Asthma

United States
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Germany, Hungary, Romania, Denmark, Greece, Mexico, Iceland
AstraZeneca

Completed

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler (REALITY)

Perception of Physicians & Patients of AMD
AstraZeneca

Completed

A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects

Asthma

United States
AstraZeneca

Completed

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
Maisonneuve-Rosemont Hospital
The Canadian Blood and Marrow Transplant Group

Terminated

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Respiratory Tract Infections | Lung Diseases, Interstitial | Bronchiolitis Obliterans | Cryptogenic Organizing Pneumonia

Canada
AstraZeneca

Completed

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

COPD Method Evaluation | Chronic Obstructive Pulmonary Disease Method Evaluation

United Kingdom, Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
University of British Columbia
National Cancer Institute (NCI)

Completed

A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)

Lung Cancer

Canada
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
Fasa University of Medical Sciences

Unknown

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

COVID-19

Iran, Islamic Republic of
AstraZeneca

Completed

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

Asthma

Malaysia
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
AstraZeneca

Recruiting

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (ATHLOS)

Chronic Obstructive Pulmonary Disease

Germany, Spain, United States, China, Korea, Republic of, Argentina, United Kingdom, Canada
Brigham and Women's Hospital

Completed

Replication of the D58 Asthma Trial in Healthcare Claims Data

Asthma

United States
AstraZeneca

Completed

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg (CHASE 3)

Asthma

United States, Mexico, Slovakia, Panama
Romaker & Associates
Merck Sharp & Dohme LLC

Completed

Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)

Obstructive Sleep Apnea

United States
Qilu Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers

Healthy Volunteers

China
Beijing Tongren Hospital

Completed

Compare the Effect of INS Alone and Added LTRA in Treatment of SAR

Allergic Rhinitis

China
Vanderbilt University
Emory University; Children's National Research Institute

Completed

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

Asthma | Sickle Cell Disease | Acute Chest Syndrome

United States
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Pearl Therapeutics, Inc.

Withdrawn

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

COPD

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
AstraZeneca

Completed

A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.

Healthy Volunteers

United Kingdom
University Hospital, Antwerp
AstraZeneca

Completed

Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Chronic Obstructive Pulmonary Disease

Belgium
Postgraduate Institute of Medical Education and...

Completed

A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis

India
AstraZeneca

Completed

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Asthma | Severe Eosinophilic Asthma

France, Germany, Italy, United Kingdom
AstraZeneca

Completed

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Chronic Obstructive Pulmonary Disease, COPD

Sweden, France, Germany, Hungary, Poland, Canada, Australia, Slovakia, Spain
AstraZeneca

Active, not recruiting

Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece (TRIAENA)

Pulmonary Disease, Chronic Obstructive (COPD)

Greece
Novartis Pharmaceuticals

Withdrawn

Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics

Asthma

Turkey
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Completed

Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT (Alloforb)

Obstructive Airway Disease

France
Eurofarma Laboratorios S.A.

Completed

A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma (CAINAS)

ASTHMA

Brazil
AstraZeneca

Completed

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma

Germany
University of Oxford

Terminated

STerOids in COVID-19 Study (STOIC)

Coronavirus Infection

United Kingdom
AstraZeneca

Completed

Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children

Asthma
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Shenzhen People's Hospital; China-Japan Friendship Hospital; Central... and other collaborators

Recruiting

The Efficacy of Budesonide/Formoterol in Cough Variant Asthma

Cough Variant Asthma

China
Organon and Co

Completed

Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)

Perennial Allergic Rhinitis
AstraZeneca

Completed

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Asthma

Netherlands
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Asthma

United States
Bond Avillion 2 Development LP

Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (MANDALA)

Asthma

United States, Canada, Germany, Spain, South Africa, United Kingdom, Slovakia, Argentina, Ukraine, Serbia, Czechia
AstraZeneca

Completed

Atlantis Symbicort

Asthma
Hat Yai Medical Education Center

Completed

Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma

Asthma

Thailand
AstraZeneca

Completed

Symbicort Onset of Action 1

Asthma
Dr. Michael Dunn

Withdrawn

Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study

Bronchopulmonary Dysplasia

Canada
NovaMed Pharmaceuticals Inc.

Unknown

Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma

Asthma

China
Orion Corporation, Orion Pharma

Terminated

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway (BufoSwitch)

Asthma | COPD

Norway

3

Subscribe